Related Experiment Video

Updated: Jun 23, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Tinea capitis in early infancy treated with itraconazole: a pilot study

B Binder1, E Richtig, W Weger

  • 1Department of Dermatology, Medical University of Graz, Graz, Austria. barbara.binder@klinikum-graz.at

Journal of the European Academy of Dermatology and Venereology : JEADV
|May 21, 2009
PubMed
Abstract

Insights

Itraconazole effectively treated Microsporum canis tinea capitis in infants. This study found itraconazole (given at 5mg/kg daily) to be safe and well-tolerated in this young population.

Area of Science:

  • Dermatology
  • Pediatric Mycology
  • Pharmacology

Background:

  • Tinea capitis, a common childhood scalp fungal infection, is rare in infants under one year.
  • Microsporum canis is a frequent cause of tinea capitis.

Purpose of the Study:

  • To assess the efficacy, tolerability, and safety of itraconazole for treating tinea capitis in infants.
  • To evaluate itraconazole's use in children aged 3 to 46 weeks caused by Microsporum canis.

Main Methods:

  • A prospective case note study was conducted.
  • Diagnostic methods included KOH testing and fungal cultivation on Sabouraud dextrose agar.
  • Treatment involved daily itraconazole at 5mg/kg for 3-6 weeks.

Main Results:

  • Seven infants (5 female, 2 male) diagnosed with Microsporum canis tinea capitis were treated.
  • All patients received itraconazole without reported side effects.
  • Clinical and mycological cure was achieved in all participants.

Conclusions:

  • Itraconazole is a safe and effective treatment for Microsporum canis-induced tinea capitis in infants.
  • The study supports itraconazole's use in the first year of life for this condition.

More Related Videos

Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth11:06

Daily Phototherapy with Red Light to Regulate Candida albicans Biofilm Growth

Published on: April 23, 2019

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...